Outcomes of children with idiopathic steroid resistant nephrotic syndrome: a single centre observational study

被引:0
作者
Mishra, Om P. [1 ]
Sidar, Minketan [1 ]
V. Batra, Vineeta [2 ]
Prasad, Rajniti [1 ]
Singh, Ankur [1 ]
Abhinay, Abhishek [1 ]
Mishra, Akash [3 ]
Yadav, Ashish K. [4 ]
机构
[1] Banaras Hindu Univ, Inst Med Sci, Dept Pediat, Div Pediat Nephrol, Varanasi, India
[2] GB Pant Inst Postgrad Med Educ & Res, Dept Pathol, New Delhi, India
[3] Jawaharlal Inst Postgrad Med Educ & Res, Dept Biostat, Pondicherry, India
[4] Banaras Hindu Univ, Inst Med Sci, Ctr Biostat, Varanasi, India
来源
JORNAL BRASILEIRO DE NEFROLOGIA | 2023年 / 45卷 / 02期
关键词
Nephrotic Syndrome; Steroid resistant; Remission; Kidney Function survival; GUIDELINES; MANAGEMENT; MUTATIONS; DISEASE;
D O I
10.1590/2175-8239-JBN-2022-0073en
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Idiopathic steroid resistant nephrotic syndrome (SRNS) has variable outcomes in children. The primary objective of the present study was to assess the cumulative remission rate and the secondary objectives were to assess factors affecting the remission status, kidney function survival, and adverse effects of medications. Methods: One hundred fourteen patients with SRNS were included. Calcineurin inhibitor-based treatment protocol along with prednisolone and angiotensin-converting enzyme inhibitor were used, and patients were followed over 5 years. Results: Median age was 4.5 years; 53.5% of cases were between 1 to 5 years of age. Sixty-two patients (54.4%) were at initial stage and 52 (45.6%) were at a late SRNS stage. Median eGFRcr was 83.5 mL/ min/1.73m2 at presentation. Of the 110 patients, 63 (57.3%) achieved remission [complete remission 30 (27.3%), partial remission 33 (30%)], and 47 (42.7%) had no remission. Kidney function survival was 87.3% and 14 cases (12.7%) had progression to CKD (G3-8, G4-3, G5-1, and G5D-2). Median duration of follow up was 36 months (IQR 24, 60). Age of onset, cyclosporine/tacrolimus, eGFRcr, and histopathology (MCD/FSGS) did not affect remission. Similarly, remission status in addition to age of onset, drug protocol, and histopathology did not significantly affect kidney function during a period of 5 years. Hypertension, cushingoid facies, short stature, cataract, and obesity were observed in 37.7, 29.8, 25.5, 17.5, and 0.7% of cases, respectively. Conclusion: About half of the cases achieved remission. Age of onset of disease, cyclosporine/tacrolimus use, and histopathological lesion neither affected remission status nor short-term kidney function survival in SRNS.
引用
收藏
页码:199 / 209
页数:11
相关论文
共 50 条
  • [21] Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression
    Agnes Trautmann
    Svenja Seide
    Beata S. Lipska-Ziętkiewicz
    Fatih Ozaltin
    Maria Szczepanska
    Marta Azocar
    Augustina Jankauskiene
    Alexandra Zurowska
    Salim Caliskan
    Bassam Saeed
    William Morello
    Francesco Emma
    Mieczyslaw Litwin
    Alexey Tsygin
    Svitlana Fomina
    Anna Wasilewska
    Anette Melk
    Elisa Benetti
    Jutta Gellermann
    Natasa Stajic
    Marcin Tkaczyk
    Sergey Baiko
    Larisa Prikhodina
    Dagmar Csaicsich
    Anna Medynska
    Regina Krisam
    Heike Breitschwerdt
    Franz Schaefer
    Pediatric Nephrology, 2023, 38 : 1499 - 1511
  • [22] Impact of initial steroid response on transplant outcomes in children with steroid-resistant nephrotic syndrome
    Francis, Anna
    Prestidge, Chanel
    Kausman, Joshua
    Le Page, Amelia
    Larkins, Nicholas
    McCarthy, Hugh
    PEDIATRIC NEPHROLOGY, 2022, 37 (05) : 1149 - 1156
  • [23] Genetic analysis and outcomes of Omani children with steroid-resistant nephrotic syndrome
    Al Riyami, Mohamed S. S.
    Al Alawi, Intisar
    Al Gaithi, Badria
    Al Maskari, Anisa
    Al Kalbani, Naifain
    Al Hashmi, Nadia
    Al Balushi, Aisha
    Al Shahi, Maryam
    Al Saidi, Suliman
    Al Bimani, Muna
    Al Hatali, Fahad
    Mabillard, Holly
    Sayer, John A. A.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2023, 11 (09):
  • [24] Impact of initial steroid response on transplant outcomes in children with steroid-resistant nephrotic syndrome
    Anna Francis
    Chanel Prestidge
    Joshua Kausman
    Amelia Le Page
    Nicholas Larkins
    Hugh McCarthy
    Pediatric Nephrology, 2022, 37 : 1149 - 1156
  • [25] A Single-Center, Cross-Sectional Study of Children with Steroid-Resistant Nephrotic Syndrome in Southern China
    Zheng, Fangfang
    Zhong, Beilong
    Chen, Lizhi
    Jiang, Mengjie
    Guo, Xinming
    Rong, Liping
    Jiang, Xiaoyun
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2021, 15 (02) : 101 - 108
  • [26] Hypothyroidism in children with steroid-resistant nephrotic syndrome
    Dagan, Amit
    Cleper, Roxana
    Krause, Irit
    Blumenthal, Danit
    Davidovits, Miriam
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2171 - 2175
  • [27] Mutation spectrum of gehes associated with steroid-resistant nephrotic syndrome in Chinese children
    Wang, Ying
    Dang, Xiqiang
    He, Qingnan
    Zhen, Yan
    He, Xiaoxie
    Yi, Zhuwen
    Zhu, Kuichun
    GENE, 2017, 625 : 15 - 20
  • [28] Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children
    Kang, Zhijuan
    Li, Zhihui
    Duan, Cuirong
    Wu, Tianhui
    Xun, Mai
    Ding, Yunfeng
    Zhang, Yi
    Zhang, Liang
    Yin, Yan
    PEDIATRIC NEPHROLOGY, 2015, 30 (07) : 1121 - 1129
  • [29] Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study
    Mazo, Alexandra
    Kilduff, Stella
    Pereira, Tanya
    Solomon, Sonia
    Matloff, Robin
    Zolotnitskaya, Anna
    Samsonov, Dmitry
    KIDNEY MEDICINE, 2024, 6 (03)
  • [30] Risks and renal outcomes of severe acute kidney injury in children with steroid-resistant nephrotic syndrome
    Ishiwa, Sho
    Sato, Mai
    Kamei, Koichi
    Nishi, Kentaro
    Kanamori, Toru
    Okutsu, Mika
    Ogura, Masao
    Sako, Mayumi
    Ito, Shuichi
    Orihashi, Yasushi
    Ishikura, Kenji
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (07) : 700 - 708